Amongst sufferers domestically superior, unresectable, stage 3 non-small cell lengthy most cancers (NSCLC) that has not progressed after platinum-based concurrent chemoradiation (cCRT), consolidation remedy with tiragolumab plus Tecentriq (atezolizumab) didn’t enhance unbiased evaluate facility (IRF)-assessed progression-free survival (PFS) versus normal Imfinzi (durvalumab) remedy, examine outcomes have proven.
Findings from the section 3 SKYSCRAPER-03 trial had been introduced on the 2025 ESMO Congress.
At a median follow-up of 30.7 months, the median IRF-PFS within the total inhabitants was 14.2 months in sufferers receiving the mixture versus 13.8 months in sufferers handled with Imfinzi. The 24-month PFS event-free charges had been 39% and 38.5%, respectively. The median total survival (OS) was 45.6 months versus 45.8 months, respectively. The 24-month OS event-free charges had been 67% versus 66.3%, respectively.
Glossary
Impartial evaluate facility (IRF)-assessed progression-free survival (PFS): the size of time a affected person lives with out their most cancers rising or spreading, as decided by a gaggle of knowledgeable docs who evaluate the scans independently from the examine docs.
Total survival (OS): the share of individuals in a examine who’re nonetheless alive after a sure time frame.
ECOG efficiency standing: a scale that docs use to explain a affected person’s basic well-being and the way succesful they’re of performing peculiar every day duties.
The first finish level was additionally missed in PD-L1–constructive sufferers with a median IRF-PFS of 19.4 months versus 16.6 months in sufferers handled with the mixture versus Imfinzi, respectively. The median OS in these sufferers was not estimable versus 54.8 months, respectively. The 24-month PFS and OS event-free survival charges had been 46.1% versus 42.9% and 72.2% versus 69.2%, respectively.
“SKYSCRAPER-03 didn’t meet its major finish level of IRF-PFS. There have been no new or surprising [safety] findings,” mentioned first examine writer Dr. Rafal Dziadziuszko, division of oncology and radiotherapy of the Medical College of Gdansk, Poland.
What Was the Security Profile of the Mixture and Monotherapy Arms within the Trial?
“Tiragolumab plus [Tecentriq] demonstrated a tolerable security profile, in keeping with earlier observations for the mixture,” mentioned Dziadziuszko.
Grade 3 (extreme)/4 (life-threatening) treatment-related unwanted side effects occurred in 13.8% of sufferers within the mixture arm, with severe treatment-related unwanted side effects skilled by 11.5%. There have been two affected person deaths thought-about to be associated to the mixture therapy. Within the Imfinzi arm, grade 3/4 treatment-related unwanted side effects and severe treatment-related unwanted side effects every occurred in 10.7% of sufferers. There have been seven affected person deaths thought-about to be associated to Imfinzi therapy.
What Was the Examine Rationale and Design for the Trial?
Relating to the rationale for the examine, Dziadziuszko defined, “Consolidation [Imfinzi] is the usual of look after sufferers with unresectable, stage 3 NSCLC that has not progressed following cCRT; nevertheless, illness recurrence [still] represents an unmet want.”
He added that the immune checkpoint goal TIGIT has a job in most cancers immune evasion and the examine speculation was that tiragolumab, an anti-TIGIT monoclonal antibody, may probably increase antitumor exercise when utilized in mixture with immunotherapies equivalent to Tecentriq.
The open-label section 3 trial was launched to check this speculation in sufferers with newly identified, unresectable, stage 3 NSCLC whose illness has not progressed following at the very least two cycles of definitive platinum-based cCRT. Sufferers needed to have recognized PD-L1 standing and an ECOG efficiency standing of 0 or 1. Sufferers with EGFR- or ALK-positive tumors weren’t eligible for enrollment.
At 1 to 42 days submit cCRT, sufferers had been randomized to mixture remedy with tiragolumab (840 mg IV each 4 weeks) plus Tecentriq (1680 mg IV each 4 weeks) or single-agent Imfinzi (10 mg/kg IV each two weeks or 1500 mg IV each 4 weeks). Affected person may obtain as much as 13 cycles of therapy (28-day cycles).
What Had been the Affected person Traits within the Trial?
Affected person traits had been effectively balanced between the 2 examine arms. The median age was 64 years within the mixture arm versus 65 years within the Imfinzi arm. About half of sufferers in every arm had been aged lower than 65 years at 50.8% and 47.4%, respectively. About 80% of sufferers in every arm had been male, about 60% had been White and about 35% had been Asian. Sufferers’ ECOG efficiency standing was principally cut up evenly between 0 and 1, with a barely increased variety of sufferers in every arm at ECOG 1 standing. About 75% of sufferers in every arm had been former tobacco customers and about 20% had been present tobacco customers.
Reference
- “SKYSCRAPER-03: Section III, open-label, randomised examine of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in domestically superior, unresectable, stage III non-small cell lung most cancers (NSCLC) after platinum-based concurrent chemoradiation (cCRT),” Dr. Rafal Dziadziuszko et al, introduced at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Summary LBA69.
For extra information on most cancers updates, analysis and schooling,
